Inventor · disambiguated record
Nicolas Poirier
Also filed as: POIRIER NICOLAS
23 granted patents·36 pending applications·59 citations·filing 2011–2025
93Inventor score
Files withOSE IMMUNOTHERAPEUTICS45FIRMENICH & CIE5INST NAT SANTE RECH MED3EFFIMUNE2BESSIS ANNE-SOPHIE1
Top patents by PatentIndex Score
59 records- 0190US8785604B2Anti-CD28 humanized antibodiesMARY CAROLINE·Filed 2011·Granted Jul 22, 2014·29 cites·14 claims
- 0287US11279766B2Anti-SIRPa antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Mar 22, 2022·3 cites·47 claims
- 0383US2024294659A1Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious DiseasesOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 0482US10364287B2Anti-CD28 humanized antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2016·Granted Jul 30, 2019·3 cites·14 claims
- 0581US11352430B2Humanized anti-human-PD-1 antibody and its use in cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2019·Granted Jun 7, 2022·2 cites·15 claims
- 0681US10428152B2Antibodies directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2015·Granted Oct 1, 2019·3 cites·11 claims
- 0781US2024279352A1Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancerOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 0880US12371502B2Antibodies directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jul 29, 2025·0 cites·21 claims
- 0980US11440964B2Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibodyOSE IMMUNOTHERAPEUTICS·Filed 2019·Granted Sep 13, 2022·2 cites·17 claims
- 1080US11365257B2Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)INST NAT SANTE RECH MED·Filed 2017·Granted Jun 21, 2022·2 cites·10 claims
- 1180US11230602B2Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Jan 25, 2022·2 cites·28 claims
- 1279US2024400695A1Methods for promoting t cells responseINST NAT SANTE RECH MED·Filed 2024·Application pending·0 cites
- 1379US2024352135A1Antibodies and polypeptides directed against cd127OSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 1478US11098128B2Antibodies and polypeptides directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2017·Granted Aug 24, 2021·1 cites·26 claims
- 1577US2024384349A1Biomarkers for assessing the response status for treatment of inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patientsOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 1676US12252546B2Anti-SIRPa antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Mar 18, 2025·0 cites·23 claims
- 1776US9562098B2Anti-CD28 humanized antibodiesEFFIMUNE·Filed 2014·Granted Feb 7, 2017·3 cites·12 claims
- 1876US9447182B2Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidatesEFFIMUNE·Filed 2012·Granted Sep 20, 2016·6 cites·13 claims
- 1975US12091464B2Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)INST NAT SANTE RECH MED·Filed 2022·Granted Sep 17, 2024·0 cites·9 claims
- 2075US8883826B2Alkynyl derivatives as modulators of metabotropic glutamate receptorsBESSIS ANNE-SOPHIE·Filed 2011·Granted Nov 11, 2014·3 cites·19 claims
- 2174US2025215108A1ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONSOSE IMMUNOTHERAPEUTICS·Filed 2025·Application pending·0 cites
- 2272US11926671B2Antibodies and polypeptides directed against CD127OSE IMMUNOTHERAPEUTICS·Filed 2021·Granted Mar 12, 2024·0 cites·17 claims
- 2372US2022281993A1Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious DiseasesOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2471US2022298259A1Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancerOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 2570US12331118B2Humanized anti-human-PD-1 antibody and methods of using them for cancer treatmentOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jun 17, 2025·0 cites·9 claims
- 2670US2024400698A1Anti-chemokin like receptor 1 antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2024·Application pending·0 cites
- 2769US12331115B2Uses of anti-SIRPg antibodiesOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Jun 17, 2025·0 cites·3 claims
- 2865US2025297324A1Biomarkers of IL7R Modulator ActivityOSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 2963US2025250354A1New class of molecules for selective clearance of antibodyOSE IMMUNOTHERAPEUTICS·Filed 2023·Application pending·0 cites
- 3061US2025340632A1SPECIFIC ANTAGONIST ANTI-SIRPg ANTIBODIESOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 3161US2023087125A1Chimeric antigen receptors targeting cd127 and use thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Application pending·0 cites
- 3260US12077820B2Biomarkers for assessing the response status for treatment of Inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patientsOSE IMMUNOTHERAPEUTICS·Filed 2018·Granted Sep 3, 2024·0 cites·9 claims
- 3360US2024368068A1Process for preparing perfuming intermediatesFIRMENICH & CIE·Filed 2022·Application pending·0 cites
- 3458US2025154090A1Process for preparing gamma,delta-unsaturated aldehydes derivativesFIRMENICH & CIE·Filed 2023·Application pending·0 cites
- 3558US2025171390A1Process for preparing unsaturated aldehydesFIRMENICH & CIE·Filed 2023·Application pending·0 cites
- 3657US2025026839A1Identification of CLEC-1 Ligand and Uses ThereofOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 3757US2023227565A1Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 AgentOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 3855US12448454B2Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereofOSE IMMUNOTHERAPEUTICS·Filed 2022·Granted Oct 21, 2025·0 cites·18 claims
- 3955US2024182571A1New scaffold for bifunctional molecules with improved propertiesOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 4055US2024182572A1Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domainsOSE IMMUNOTHERAPEUTICS·Filed 2022·Application pending·0 cites
- 4154US2018312600A1Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancerOSE IMMUNOTHERAPEUTICS·Filed 2016·Application pending·0 cites
- 4254US2024067727A1Bifunctional anti-pd1/il-7 moleculesOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 4354US2025171391A1Process for preparing octahydro-2(1h)-naphthalenone derivativesFIRMENICH & CIE·Filed 2023·Application pending·0 cites
- 4452US2021147558A1Anti-chemokin like receptor 1 antibodies and their therapeutic applicationsOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 4551US11713356B2Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancerOSE IMMUNOTHERAPEUTICS·Filed 2018·Granted Aug 1, 2023·0 cites·34 claims
- 4651US2023365523A1Process for preparing 3-(cyclohex-1-en-1-yl)propanal derivativesFIRMENICH & CIE·Filed 2021·Application pending·0 cites
- 4750US2022056135A1Bifunctional anti-pd-1/sirpa moleculeOSE IMMUNOTHERAPEUTICS·Filed 2019·Application pending·0 cites
- 4850US2023181721A1Vaccine against sars-cov virusOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
- 4950US2023331852A1Anti-clec-1a antibodies and antigen-binding fragment thereofOSE IMMUNOTHERAPEUTICS·Filed 2020·Application pending·0 cites
- 5049US2022389104A1Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 AgentOSE IMMUNOTHERAPEUTICS·Filed 2021·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Nicolas Poirier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →